Inventor · disambiguated record
Thomas N. Chase
Also filed as: CHASE THOMAS N
28 granted patents·26 pending applications·108 citations·filing 2009–2022
95Inventor score
Files withCHASE PHARMACEUTICALS CORP25CHASE THERAPEUTICS CORP18CHASE THOMAS N4AVION PHARMACEUTICALS LLC3NC MEDICAL RES INC3
Top patents by PatentIndex Score
54 records- 0193US9278092B2Method and composition for treating alzheimer-type dementiaCHASE PHARMACEUTICALS CORP·Filed 2014·Granted Mar 8, 2016·17 cites·14 claims
- 0293US8404701B2Use and composition for treating dementiaCHASE THOMAS N·Filed 2009·Granted Mar 26, 2013·24 cites·13 claims
- 0392US9561218B2Anticholinergic neuroprotective composition and methodsCHASE PHARMACEUTICALS CORP·Filed 2013·Granted Feb 7, 2017·17 cites·3 claims
- 0492US8877768B2Method and composition for treating alzheimer-type dementiaCHASE THOMAS N·Filed 2010·Granted Nov 4, 2014·18 cites·14 claims
- 0589US11160809B2NK1-antagonist combination and method for treating synucleinopathiesCHASE THERAPEUTICS CORP·Filed 2018·Granted Nov 2, 2021·4 cites·23 claims
- 0687US11266633B2NK-1 antagonist compositions and methods for use in treating depressionCHASE THERAPEUTICS CORP·Filed 2018·Granted Mar 8, 2022·5 cites·10 claims
- 0785US9192591B2Method and composition for treating alzheimer-type dementiaCHASE PHARMACEUTICALS CORP·Filed 2014·Granted Nov 24, 2015·3 cites·22 claims
- 0884US11547700B2Compositions and methods for treating synucleinopathiesCHASE THERAPEUTICS CORP·Filed 2020·Granted Jan 10, 2023·1 cites·11 claims
- 0984US9744161B2Method and composition for treating alzheimer-type dementiaCHASE PHARMACEUTICALS CORP·Filed 2016·Granted Aug 29, 2017·3 cites·38 claims
- 1083US9913836B2Anticholinergic neuroprotective composition and methodsCHASE PHARMACEUTICALS CORP·Filed 2016·Granted Mar 13, 2018·3 cites·11 claims
- 1182US10548855B2Memantine combinations and useCHASE PHARMACEUTICALS CORP·Filed 2017·Granted Feb 4, 2020·1 cites·8 claims
- 1282US9943508B2Method and composition for treating Alzheimer-type dementiaCHASE PHARMACEUTICALS CORP·Filed 2017·Granted Apr 17, 2018·2 cites·23 claims
- 1379US11033521B2Levodopa fractionated dose composition and useAVION PHARMACEUTICALS LLC·Filed 2019·Granted Jun 15, 2021·2 cites·20 claims
- 1479US10799484B2Compositions and methods for treating synucleinopathiesCHASE THERAPEUTICS CORP·Filed 2018·Granted Oct 13, 2020·2 cites·17 claims
- 1578US10307409B2Muscarinic combinations and their use for combating hypocholinergic disorders of the central nervous systemCHASE PHARMACEUTICALS CORP·Filed 2016·Granted Jun 4, 2019·1 cites·3 claims
- 1677US11819485B2Levodopa fractionated dose composition and useAVION PHARMACEUTICALS LLC·Filed 2022·Granted Nov 21, 2023·0 cites·44 claims
- 1777US11813248B2NK-1 antagonist compositions and methods for use in treating depressionCHASE THERAPEUTICS CORP·Filed 2022·Granted Nov 14, 2023·0 cites·5 claims
- 1877US10195187B2Oxybutynin-xanomeline transdermal therapeutic system combinationsCHASE PHARMACEUTICALS CORP·Filed 2016·Granted Feb 5, 2019·1 cites·4 claims
- 1975US11813247B2NK-1 antagonist compositions and methods for use in treating depressionCHASE THERAPEUTICS CORP·Filed 2022·Granted Nov 14, 2023·0 cites·6 claims
- 2075US2020121656A1Method and composition for treating alzheimer-type dementiaCHASE PHARMACEUTICALS CORP·Filed 2019·Application pending·0 cites
- 2173US11318122B2Pharmaceutical combination and its use for treating synucleinopathtiesCHASE THERAPEUTICS CORP·Filed 2018·Granted May 3, 2022·1 cites·7 claims
- 2273US9896416B2Piperidinium quaternary saltsCHASE PHARMACEUTICALS CORP·Filed 2013·Granted Feb 20, 2018·1 cites·9 claims
- 2373US9044472B2Use and composition for treating dementiaCHASE PHARMACEUTICALS CORP·Filed 2014·Granted Jun 2, 2015·1 cites·17 claims
- 2471US11439613B2Levodopa fractionated dose composition and useAVION PHARMACEUTICALS LLC·Filed 2021·Granted Sep 13, 2022·0 cites·29 claims
- 2569US10149828B2Oxybutynin transdermal therapeutic system combinationCHASE PHARMACEUTICALS CORP·Filed 2016·Granted Dec 11, 2018·1 cites·4 claims
- 2665US2020253893A1Memantine combinations and useCHASE PHARMACEUTICALS CORP·Filed 2019·Application pending·0 cites
- 2763US2019091214A1Use and composition for treating dementiaCHASE PHARMACEUTICALS CORP·Filed 2018·Application pending·0 cites
- 2862US2019365736A1Anticholinergic neuroprotective composition and methodsCHASE PHARMACEUTICALS CORP·Filed 2019·Application pending·0 cites
- 2962US2018296540A1Method and composition for treating alzheimer-type dementiaCHASE PHARMACEUTICALS CORP·Filed 2017·Application pending·0 cites
- 3062US2019314354A1Muscarinic combinations and their use for combating hypocholinergic disorders of the central nervous systemCHASE PHARMACEUTICALS CORP·Filed 2019·Application pending·0 cites
- 3161US2020171014A1Oxybutynin-xanomeline transdermal therapeutic system combinationsCHASE PHARMACEUTICALS CORP·Filed 2018·Application pending·0 cites
- 3259US10874723B2Cell therapy for the treatment of neurodegenerationNC MEDICAL RES INC·Filed 2018·Granted Dec 29, 2020·0 cites·14 claims
- 3359US2025329454A1Diagnostic indices for neurodegenerative conditionsCHASE THERAPEUTICS CORP·Filed 2022·Application pending·0 cites
- 3458US2019000826A1Anticholinergic neuroprotective composition and methodsCHASE PHARMACEUTICALS CORP·Filed 2018·Application pending·0 cites
- 3558US2013158012A1Use and composition for treating dementiaCHASE THOMAS N·Filed 2013·Application pending·0 cites
- 3655US2020375957A1Compositions and method for treating depressionCHASE THERAPEUTICS CORP·Filed 2018·Application pending·0 cites
- 3754US2022000854A1Domperidone antineurodegenerative combinations and useCHASE THERAPEUTICS CORP·Filed 2019·Application pending·0 cites
- 3854US2022214360A1Alpha-synuclein assaysCHASE THERAPEUTICS CORP·Filed 2020·Application pending·0 cites
- 3953US2021393595A1Anti-neurodegenerative combinations and use for treatment of neurodegenerative diseasesCHASE THERAPEUTICS CORP·Filed 2019·Application pending·0 cites
- 4053US2023349906A1Kinases as biomarkers for neurodegenerative conditionsCHASE THERAPEUTICS CORP·Filed 2020·Application pending·0 cites
- 4153US2015224096A1Use and composition for treating dementiaCHASE PHARMACEUTICALS CORP·Filed 2015·Application pending·0 cites
- 4252US2011201597A1Method and composition for treating alzheimer-type dementiaCHASE THOMAS N·Filed 2011·Application pending·0 cites
- 4350US10071144B2Cell therapy for the treatment of neurodegenerationNC MEDICAL RES INC·Filed 2013·Granted Sep 11, 2018·0 cites·6 claims
- 4449US10149894B2Cell therapy for the treatment of neurodegenerationNC MEDICAL RES INC·Filed 2017·Granted Dec 11, 2018·0 cites·9 claims
- 4548US2020113899A1Statin compositions and methods for use in treating synucleinopathiesCHASE THERAPEUTICS CORP·Filed 2018·Application pending·0 cites
- 4647US2020400687A1Methods for developing pharmaceuticals for treating neurodegenerative conditionsCHASE THERAPEUTICS CORP·Filed 2018·Application pending·0 cites
- 4746US10596139B2Oxybutynin transdermal therapeutic system muscarinic agonist combinationCHASE PHARMACEUTICALS CORP·Filed 2016·Granted Mar 24, 2020·0 cites·6 claims
- 4846US2022071976A1Domperidone compositions and methods for treating depressionCHASE THERAPEUTICS CORP·Filed 2019·Application pending·0 cites
- 4946US2021338652A1Composition and use for the treatment of parkinson's disease and related disordersCHASE THERAPEUTICS CORP·Filed 2019·Application pending·0 cites
- 5043US2018360845A1Muscarinic combination of a selective m2-antagonist and a peripheral non-selective antagonist for treating hypocholinergic disordersCHASE PHARMACEUTICALS CORP·Filed 2016·Application pending·0 cites
Showing the top 50 of 54 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Thomas N. Chase files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →